ECONOMIC-ANALYSIS OF TIRILAZAD MESYLATE FOR ANEURYSMAL SUBARACHNOID HEMORRHAGE - ECONOMIC-EVALUATION OF A PHASE-III CLINICAL-TRIAL IN EUROPE AND AUSTRALIA

This study used data from a multinational phase III randomized, double -blind, vehicle-controlled trial to evaluate the cost-effectiveness of tirilazad mesylate (Freedox(R)) in the treatment of aneurysmal subara chnoid hemorrhage. In men, therapy with 6 mg/kg per day of tirilazad m esylate was associated with significantly increased survival, increase d cost of care, and ratios of cost per death averted that compare favo rably with the ratios of other life and death interventions. In women, it appeared to have no effects on costs or survival. Further clinical studies may provide additional information about the cost-effectivene ss of this intervention.